 |
|
 |
 |

Home > Company Index > Drugs > Biotechnology-Research > Kosan Biosciences Incorporated
 |
Kosan Biosciences Incorporated |
 |
 |
 |
PROFILE |
 |
Kosan Biosciences is manipulative -- but in a good way. The development-stage firm alters naturally occurring polyketides to produce new classes or improve upon existing classes of pharmaceuticals. Polyketides are produced by microorganisms and used to make such drugs as Zithromax, an antiobiotic from Pfizer, and Pravacol, a cholesterol fighter from Bristol-Myers Squibb. Kosan targets infectious diseases, gastrointestinal disorders, mucus hypersecretion (a symptom of such conditions as asthma, cystic fibrosis, and allergies), cancer, immunosuppression, and nerve regeneration. Partners include Johnson & Johnson unit The R.W. Johnson Pharmaceutical Research Institute, Stanford University, and Harvard University.
COMPETITION |
 |
Aventis (AVE)
Eli Lilly and Company (LLY)
Pfizer Inc (PFE)
|
 |
STOCK ANALYSIS |
 |
FURTHER ANALYSIS
Advanced Charting
Deals
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: December
2000 Sales (mil.): 4.20
1-Yr. Sales Growth: (20.8)%
Employees: 81
Revenue per employee: $51,851.85
KEY PEOPLE |
 |
Daniel V. Santi
CEO
Susan M. Kanaya
CFO
CONTACT INFO |
 |
3832 Bay Center Place
Hayward, CA 94545
US
Phone: 510-732-8400
Fax: 510-732-8401
Online: Web Site
|
 |
 |
 |
|
Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.
|

|
 |
 |
|
 |